

RECEIVED
CENTRAL FAX CENTER

FEB 16 2007


REMARKS

In response to the requirement to elect a specific potent active ingredient for the generic group of active ingredients (page 12, line 15 of the Office Action of October 5, 2006), the applicant elects metformin, with traverse. As for the election of a specific type of high solubility active ingredients (page 12, line 17 of the Office Action of October 5, 2006) the applicants elect perindpril erbumine, with traverse.

This election of species requirement is made with traverse as the Examiner has not shown that the separately identified inventions are independent and distinct inventions. The Examiner has required election of a "specific potent active ingredient for the generic group of ingredient". No reference was made to the following list of "Specific type of High Solubility Potent Active Ingredients" so the election was made to metformin which is a species of the "antidiabetic agents" because no antidiabetic agent was listed in the group of compounds identified by the Examiner as Type of High Solubility Potent Active Ingredient. To be complete, perindpril erbumine was elected from the list of Type of Active Ingredient.

An early and favorable action on all Claims is earnestly solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'JVC', with a large, sweeping flourish extending from the end of the signature.

James V. Costigan
Registration No. 25,669

Hedman & Costigan, P.C.
1185 Avenue of the Americas
New York, NY 10036
(212) 302-8989